- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05893316
UroCAD for hæmaturi-evaluering - en prospektiv multicenterundersøgelse
Hæmaturi-evaluering ved hel-genom-sekventering af urin-eksfolieret celle-DNA, en prospektiv, multi-center undersøgelse
Hematuria is recognized as an important sigh of potential urinary tract malignancy. Therefore, understanding the disease processes and discovering the potential urothelial carcinoma (UC) underlying this important sign is critical. Cystoscopy, urine cytology and imaging are most reliable methods for UC diagnosis, but certain drawbacks exist for these methods, such as invasiveness or inaccuracy. Chromosomal instability (CIN) is a hallmark of human cancer, and it's related with tumor stage and grade. Previous research has proved that analyzing CIN of the DNA extracted from urothelial cells in urine samples seems a promising method for detecting UC. Here the investigators intend to assess CIN's performance for hematuria evaluation.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Hematuria is defined as the presence of 3 or more red blood cells per high-power field (RBC/HPF) under microscopic examination of the urine, which is an important sigh of genitourinary system disease, especially UC. Several methods can be adopted for hematuria evaluation. Cystoscopy is a key component of the hematuria evaluation because it is a reliable way to evaluate the bladder and urethra. Biopsy can also be performed through cystoscopy, making it the "gold standard" for bladder cancer diagnosis. Despite its high reliability and accuracy, it's an invasive examination related with complications such as injury to the urethra, infection, and discomfort. Flat lesions may also be omitted under cystoscopy. Urine cytology is another important method for UC evaluation, but it has a sensitivity of only 15.8%-54.5%.
CIN refers to the ongoing acquisition of genomic alterations, it can range from point mutations to small-scale genomic alterations and gross chromosomal rearrangements. 60%-80% of human tumors exhibit chromosomal abnormalities suggestive of CIN. CIN is presented in UC and it has been adopted as a diagnostic method for UC, such as UroVysion test. Previously, CIN detected by low-coverage whole genome sequencing proved to be a reliable method for UC diagnosis and was named as Urine Exfoliated Cells Copy Number Aberration Detector (UroCAD). In this prospective, multi-canter, observational clinical trial, the investigators intend to assess the possibility of UroCAD as an additional diagnostic tool for hematuria patients by collecting and analyzing 30 ml of urine sample from hematuria patient across 5 centers.
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina, 200433
- Changhai Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Patients presented with hematuria (≥ 3 RBCs/HPF) and patients with malignancy other than urothelial carcinoma in Changhai Hospital, Tongji Hospital, Renji Hospital, First Affiliated Hospital of Xian Jiaotong University, and Gulou Hospital.
Beskrivelse
Inclusion Criteria:
-
Participants aged ≥ 18 years and signed informed consent form.
-
Participants presented with hematuria (≥ 3 RBCs/HPF) and meet one of the following criteria:
- Patients recommended to undergo cystoscopy or ureteroscopy;
- Patients with treatment-naïve, pathology-confirmed urothelial carcinoma;
- Patients diagnosed with benign genitourinary disease.
-
Participants diagnosed with cancer other than urothelial carcinoma.
Exclusion Criteria:
- Participants with history of urothelial carcinoma.
- Participants with urothelial carcinoma accompanied by other malignancy.
- Individuals unwilling to sign the consent form or unwilling to provide urine sample for test or quality of urine sample is poor.
- Patients unsuitable for this clinical trial.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Hematuria patients
Hematuria patients (≥ 3 RBCs/HPF) with treatment-naïve, pathology-confirmed urothelial carcinoma or benign genitourinary system disease or with undetermined lesion presented with hematuria. |
The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN. |
|
Non-hematuria patients
Patients without hematuria and diagnosed with pathology-confirmed cancer other than urothelial cancer. |
The level of CIN The extracted DNA from urine exfoliated cells will be analyzed by UroCAD to determine the level of CIN. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
sensitivity
Tidsramme: through study completion, an average of 8 months
|
Comparison of the sensitivity of the UroCAD analysis versus clinically-acceptable threshold, defined as 75%. |
through study completion, an average of 8 months
|
|
specificity
Tidsramme: through study completion, an average of 8 months
|
Comparison of the specificity of the UroCAD analysis versus clinically-acceptable threshold, defined as 95%. |
through study completion, an average of 8 months
|
|
Sensitivity among hematuria patients
Tidsramme: through study completion, an average of 8 months
|
Sensitivity of UroCAD in detecting urothelial carcinoma among hematuria patients |
through study completion, an average of 8 months
|
|
Specificity among hematuria patients
Tidsramme: through study completion, an average of 8 months
|
Specificity of UroCAD in detecting urothelial carcinoma among hematuria patients |
through study completion, an average of 8 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Comparison of Sensitivity
Tidsramme: through study completion, an average of 8 months
|
Comparison of the sensitivity of the UroCAD analysis versus urine cytology |
through study completion, an average of 8 months
|
|
Comparison of Specificity
Tidsramme: through study completion, an average of 8 months
|
Comparison of the Specificity of the UroCAD analysis versus urine cytology |
through study completion, an average of 8 months
|
Samarbejdspartnere og efterforskere
Publikationer og nyttige links
Generelle publikationer
- Sansregret L, Vanhaesebroeck B, Swanton C. Determinants and clinical implications of chromosomal instability in cancer. Nat Rev Clin Oncol. 2018 Mar;15(3):139-150. doi: 10.1038/nrclinonc.2017.198. Epub 2018 Jan 3.
- McDougal, W. Scott, et al. Campbell-Walsh urology 11th Edition review e-book. Elsevier Health Sciences, 2015.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Patologiske processer
- Neoplasmer
- Mandlige urogenitale sygdomme
- Urologiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Vandladningsforstyrrelser
- Neoplasmer efter histologisk type
- Blødning
- Neoplasmer, kirtel og epitel
- Karcinom
- Patologiske tilstande, tegn og symptomer
- Carcinom, overgangscelle
- Hæmaturi
Andre undersøgelses-id-numre
- CH-Hematuria-CIN
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual participant data are not public for privacy protection purpose. Data without private information may be provided on request.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .